GlassScriptPhysician profile
Vadjista Broumand
NPI 1376537308
$4,416.16
in general payments reported to CMS, 2019-2025
27 companies · $785 in 2025
The $785 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $461 · 2021: $575 · 2022: $400 · 2023: $697 · 2024: $711 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,655.16 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $344.00 | 2019-2025 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $258.01 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $183.05 | 2019-2025 | |
| Pfizer INC. | $172.11 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $165.68 | 2019-2025 | Ilumya |
| Leo Pharma INC. | $162.95 | 2019-2025 | Adbry |
| Ucb, INC. | $159.24 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $156.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $153.83 | 2023-2025 | Sotyktu |
| Incyte Corporation | $148.32 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $140.80 | 2019-2024 | |
| Lilly USA, LLC | $104.54 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sandoz INC. | $88.37 | 2019-2020 | |
| Celgene Corporation | $84.52 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $80.27 | 2019-2022 | |
| Smith+Nephew, INC. | $62.62 | 2019-2021 | |
| Kyowa Kirin, INC. | $59.57 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $48.78 | 2023-2025 | Zoryve |
| Horizon Therapeutics Plc | $46.28 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.03 | 2020 | |
| Blueprint Medicines Corporation | $27.28 | 2023 | |
| Taro Pharmaceuticals USA, INC. | $24.15 | 2019 | |
| Prugen, INC. Pharmaceuticals | $22.75 | 2019 | |
| Dermira, INC. | $14.19 | 2019 | |
| Mayne Pharma Commercial LLC | $12.93 | 2019 | |
| Merck Sharp & Dohme LLC | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vadjista Broumand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.